- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06772623
진행성 질환에 대한 사전 치료가 없고 실행 가능한 게놈 변화가 없는 진행성 또는 전이성 비편평 NSCLC 성인 참가자를 대상으로 IV 부디갈리맙과 병용한 정맥(IV) 텔리소투주맙 아디주테칸의 부작용, 효능 및 최적 용량을 평가하기 위한 연구
진행성 질병에 대한 사전 치료가 없고 실행 가능한 게놈 변경이 없는 진행성 또는 전이성 비편평 NSCLC에서 부디갈리맙과 병용한 텔리소투주맙 아디주테칸의 안전성, 유효성 및 최적 용량을 평가하기 위한 공개 라벨 다중 코호트 1b/2상 연구
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.
Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: ABBVIE CALL CENTER
- 전화번호: 844-663-3742
- 이메일: abbvieclinicaltrials@abbvie.com
연구 장소
-
-
-
Changhua, 대만, 500
- 모병
- Changhua Christian Hospital /ID# 280139
-
Chiayi City, 대만, 62247
- 모병
- Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation /ID# 268789
-
Kaohsiung City, 대만, 807
- 모병
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 268139
-
Kaohsiung City, 대만, 833
- 모병
- Kaohsiung Chang Gung Memorial Hospital /ID# 268138
-
Taipei, 대만, 114
- 모병
- Tri-Service General Hospital /ID# 269211
-
Taipei, 대만, 106
- 모병
- National Taiwan University Cancer Center (Ntucc) /ID# 271586
-
Taipei, 대만, 112
- 모병
- Taipei Veterans General Hospital /ID# 268787
-
Taoyuan City, 대만, 333
- 모병
- Linkou Chang Gung Memorial Hospital /ID# 268137
-
-
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, 독일, 79106
- 모병
- Universitaetsklinikum Freiburg /ID# 268473
-
Heilbronn, Baden-Wurttemberg, 독일, 74078
- 모병
- Slk-Kliniken Heilbronn /ID# 269621
-
-
Bavaria
-
Augsburg, Bavaria, 독일, 86150
- 모병
- Hamatologie-Onkologie im Zentrum MVZ GmbH /ID# 273043
-
Würzburg, Bavaria, 독일, 97080
- 모병
- Universitaetsklinikum Wuerzburg /ID# 275445
-
-
Hesse
-
Frankfurt am Main, Hesse, 독일, 60590
- 모병
- Universitaetsklinikum Frankfurt /ID# 268721
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, 독일, 50937
- 모병
- Universitaetsklinikum Koeln /ID# 268489
-
Hemer, North Rhine-Westphalia, 독일, 58675
- 모병
- Lungenklinik Hemer /ID# 269779
-
-
Schleswig-Holstein
-
Oldenburg in Holstein, Schleswig-Holstein, 독일, 23758
- 모병
- ohO Research GmbH /ID# 273060
-
-
Thuringia
-
Jena, Thuringia, 독일, 07747
- 모병
- Universitatsklinikum Jena /ID# 269700
-
-
-
-
-
Bucharest, 루마니아, 013975
- 모병
- MNT Healthcare Europe SRL /ID# 269075
-
Bucharest, 루마니아, 030171
- 모병
- Spitalul Clinic Coltea /ID# 268726
-
Sibiu, 루마니아, 550253
- 모병
- Clinica MedLife Polisano Sibiu /ID# 269078
-
-
Cluj
-
Cluj-Napoca, Cluj, 루마니아, 400080
- 모병
- S.C. Radiotherapy Center Cluj SRL /ID# 268729
-
Cluj-Napoca, Cluj, 루마니아, 400015
- 모병
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 273125
-
Cluj-Napoca, Cluj, 루마니아, 400015
- 모병
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 268725
-
-
-
-
Arizona
-
Phoenix, Arizona, 미국, 85054
- 모집하지 않고 적극적으로
- Mayo Clinic Hospital - Phoenix /ID# 272971
-
-
California
-
Fullerton, California, 미국, 92835
- 모병
- Providence - St. Jude Medical Center /ID# 271414
-
Oxnard, California, 미국, 93030
- 모병
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450
-
Santa Monica, California, 미국, 90404
- 모병
- UCLA - Santa Monica /ID# 271690
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- University Of Colorado - Anschutz Medical Campus /ID# 269069
-
Lone Tree, Colorado, 미국, 80124
- 모병
- Rocky Mountain Cancer Centers - Lone Tree /ID# 272603
-
-
Florida
-
Jacksonville, Florida, 미국, 32224
- 모병
- Mayo Clinic Hospital Jacksonville /ID# 275073
-
Orange City, Florida, 미국, 32763
- 모병
- Mid Florida Hematology And Oncology Center /ID# 273777
-
-
Illinois
-
Hinsdale, Illinois, 미국, 60521
- 모병
- Hope And Healing Cancer Services /ID# 276223
-
연락하다:
- Site Coordinator
- 전화번호: 6305600121
-
-
Indiana
-
Fort Wayne, Indiana, 미국, 46845
- 모병
- Parkview Comprehensive Cancer Center /ID# 271879
-
Indianapolis, Indiana, 미국, 46202
- 완전한
- Community Health Network /ID# 273437
-
-
Kansas
-
Overland Park, Kansas, 미국, 66210
- 모병
- Kansas City Cancer Center /ID# 273679
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모병
- Dana-Farber Cancer Institute /ID# 278417
-
-
Michigan
-
Detroit, Michigan, 미국, 48202
- 모병
- Henry Ford Hospital - Detroit /ID# 271642
-
-
Minnesota
-
Duluth, Minnesota, 미국, 55805
- 모병
- St. Luke'S /ID# 273344
-
Rochester, Minnesota, 미국, 55905
- 모병
- Mayo Clinic-Rochester /ID# 274512
-
-
New Jersey
-
East Brunswick, New Jersey, 미국, 08816-4096
- 모병
- Astera Cancer Care /ID# 271915
-
-
New York
-
Shirley, New York, 미국, 11967
- 모병
- New York Cancer And Blood Specialists - Shirley /ID# 272547
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106
- 완전한
- University Hospitals Cleveland Medical Center /ID# 271726
-
Columbus, Ohio, 미국, 43219
- 모병
- The Mark H Zangmeister Center /ID# 272502
-
-
Pennsylvania
-
Easton, Pennsylvania, 미국, 18045
- 모병
- Spoknwrd Clinical Trials /ID# 273776
-
연락하다:
- Site Coordinator
- 전화번호: 610-813-2087
-
-
Texas
-
Houston, Texas, 미국, 77090
- 완전한
- Millennium Physicians /ID# 271717
-
Lubbock, Texas, 미국, 79410-1121
- 모병
- Joe Arrington Cancer Research /ID# 272776
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- 모병
- Huntsman Cancer Institute /ID# 271686
-
-
Virginia
-
Leesburg, Virginia, 미국, 20176
- 모병
- Virgnia Cancer Specialists /ID# 269633
-
-
Washington
-
Olympia, Washington, 미국, 98506
- 모병
- Vista Oncology - East Olympia /ID# 275438
-
Tacoma, Washington, 미국, 98405
- 모병
- Northwest Medical Specialties Tacoma /ID# 270469
-
-
-
-
-
Liège, 벨기에, 4000
- 모병
- Groupe Sante CHC - Clinique du MontLegia /ID# 271760
-
-
Limburg
-
Hasselt, Limburg, 벨기에, 3500
- 모병
- Jessa Ziekenhuis - Campus Virga Jesse /ID# 268573
-
-
Oost-Vlaanderen
-
Sint-Niklaas, Oost-Vlaanderen, 벨기에, 9100
- 모병
- Vitaz /Id# 280187
-
-
West-Vlaanderen
-
Roeselare, West-Vlaanderen, 벨기에, 8800
- 모병
- AZ-Delta. /ID# 272433
-
-
-
-
-
A Coruña, 스페인, 15006
- 모병
- Complejo Hospitalario Universitario A Coruna /ID# 271456
-
Alicante, 스페인, 03010
- 모병
- Hospital General Universitario de Alicante /ID# 271316
-
Barcelona, 스페인, 08036
- 모병
- Hospital Clinic de Barcelona /ID# 271452
-
Barcelona, 스페인, 08041
- 모병
- Hospital Santa Creu i Sant Pau /ID# 271311
-
Barcelona, 스페인, 08003
- 모병
- Hospital del Mar /ID# 271310
-
Málaga, 스페인, 29010
- 모병
- Hospital Universitario Virgen de la Victoria /ID# 271312
-
-
Cantabria
-
Santander, Cantabria, 스페인, 39008
- 모병
- Hospital Universitario Marques de Valdecilla /ID# 271314
-
-
Sevilla
-
Seville, Sevilla, 스페인, 41009
- 모병
- Hospital Universitario Virgen Macarena /ID# 271447
-
-
-
-
-
Buenos Aires, 아르헨티나, 1426
- 모병
- Centro Oncologico Korben /ID# 281460
-
Buenos Aires, 아르헨티나, 1426
- 모병
- Fundacion Respirar /ID# 281039
-
-
Buenos Aires
-
Mar del Plata, Buenos Aires, 아르헨티나, 7600
- 모병
- Clinca Colon /ID# 281465
-
-
Buenos Aires F.D.
-
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., 아르헨티나, 1426
- 모병
- Instituto Alexander Fleming /ID# 282704
-
-
-
-
-
Cardiff, 영국, CF14 2TL
- 모병
- Velindre Cancer Centre /ID# 271840
-
-
Leicestershire
-
Leicester, Leicestershire, 영국, LE1 5WW
- 모병
- University Hospitals of Leicester NHS Trust /ID# 276035
-
-
-
-
-
Bologna, 이탈리아, 40138
- 모병
- IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 268675
-
-
Forlì-Cesena
-
Meldola, Forlì-Cesena, 이탈리아, 47014
- 모병
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 268684
-
-
Milano
-
Milan, Milano, 이탈리아, 20121
- 모병
- Istituto Europeo Di Oncologia /Id# 268670
-
-
Roma
-
Rome, Roma, 이탈리아, 00144
- 모병
- IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 268626
-
Rome, Roma, 이탈리아, 00184
- 모병
- Azienda Ospedaliera Complesso Ospedaliero San Giovanni-Addolorata /ID# 273438
-
-
The Marches
-
Ancona, The Marches, 이탈리아, 60126
- 모병
- Azienda Ospedaliero Universitaria delle Marche /ID# 268667
-
-
Torino
-
Orbassano, Torino, 이탈리아, 10043
- 모병
- Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 268641
-
-
-
-
-
Nagasaki, 일본, 852-8501
- 모병
- Nagasaki University Hospital /ID# 273310
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 460-0001
- 모병
- NHO Nagoya Medical Center /ID# 272515
-
Nagoya, Aichi-ken, 일본, 464-8681
- 모병
- Aichi Cancer Center /ID# 271978
-
-
Aomori
-
Hirosaki, Aomori, 일본, 036-8563
- 모병
- Hirosaki University Hospital /ID# 274410
-
-
Kanagawa
-
Yokohama, Kanagawa, 일본, 221-0855
- 모병
- Yokohama Municipal Citizen's Hospital /ID# 271979
-
-
Kyoto
-
Kyoto, Kyoto, 일본, 606-8507
- 모병
- Kyoto University Hospital /ID# 272312
-
-
Niigata
-
Niigata, Niigata, 일본, 951-8520
- 모병
- Niigata University Medical and Dental Hospital /ID# 274448
-
-
Osaka
-
Takatsuki, Osaka, 일본, 569-8686
- 모병
- Osaka Medical And Pharmaceutical University Hospital /ID# 273309
-
-
Tokyo
-
Chuo-Ku, Tokyo, 일본, 104-0045
- 모병
- National Cancer Center Hospital /ID# 273192
-
Koto-ku, Tokyo, 일본, 135-8550
- 모병
- The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 271989
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100021
- 모병
- Cancer Hospital - Chinese Academy of Medical Sciences /ID# 269715
-
-
Fujian
-
Fuzhou, Fujian, 중국, 350014
- 모병
- Fujian Province Cancer Hospital /ID# 269150
-
-
Guangxi
-
Liuzhou, Guangxi, 중국, 545006
- 모병
- Liuzhou People's hospital /ID# 269667
-
-
Henan
-
Zhengzhou, Henan, 중국, 450008
- 모병
- Henan Cancer Hospital /ID# 269668
-
-
Hubei
-
Wuhan, Hubei, 중국, 430022
- 모병
- Union Hospital - Tongji Medical College /ID# 272286
-
-
Hunan
-
Changsha, Hunan, 중국, 410013
- 모병
- Hunan Province Cancer Hospital /ID# 269679
-
-
Jiangsu
-
Nanjing, Jiangsu, 중국, 210008
- 모병
- Nanjing Drum Tower Hospital /ID# 269762
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 330209
- 모병
- The First Affiliated Hospital of Nanchang University - Xianghu Campus /ID# 269190
-
-
Shaanxi
-
Xi'an, Shaanxi, 중국, 710061
- 모병
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271904
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200030
- 모병
- Shanghai Chest Hospital /ID# 269155
-
Shanghai, Shanghai Municipality, 중국, 200433
- 모병
- Shanghai Pulmonary Hospital /ID# 276397
-
-
Shanxi
-
Taiyuan, Shanxi, 중국, 030001
- 모병
- First Affiliated Hospital of Shanxi Medical University /ID# 276482
-
-
Sichuan
-
Chengdu, Sichuan, 중국, 610041
- 모병
- West China Hospital of Sichuan University /ID# 270244
-
Chengdu, Sichuan, 중국, 610041
- 모병
- Sichuan Province Cancer Hospital /ID# 269712
-
-
Yunnan
-
Kunming, Yunnan, 중국, 650106
- 모병
- Yunnan Province Cancer Hospital /ID# 272331
-
-
-
-
Region Metropolitana Santiago
-
Santiago, Region Metropolitana Santiago, 칠레, 8330032
- 모병
- Pontificia Universidad Catolica De Chile /ID# 281594
-
Vitacura, Region Metropolitana Santiago, 칠레, 7650027
- 모병
- Oncored /Id# 281108
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, 칠레, 6900941
- 모병
- Fundacion Arturo Lopez Perez /ID# 281211
-
Santiago, Santiago Metropolitan, 칠레, 7500713
- 모병
- Orlandi Oncologia /ID# 281132
-
-
-
-
-
Adana, 터키 (Türkiye), 01140
- 모병
- Adana Medical Park Seyhan Hastanesi /ID# 272875
-
Ankara, 터키 (Türkiye), 06620
- 모병
- Ankara Universitesi Tip Fakultesi Cebeci Hastanesi /ID# 272873
-
Ankara, 터키 (Türkiye), 06680
- 모병
- Liv Hospital Ankara /ID# 272876
-
Ankara, 터키 (Türkiye), 06230
- 모병
- Hacettepe Universitesi Tip Fakultesi /ID# 280631
-
Denizli, 터키 (Türkiye), 20070
- 모병
- Pamukkale Universitesi /ID# 272893
-
Istanbul, 터키 (Türkiye), 34722
- 모병
- Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi /ID# 280635
-
Konya, 터키 (Türkiye), 42080
- 모병
- Necmettin Erbakan Universitesi Meram Tip Fakultesi - Eski Hastane /ID# 272882
-
Samsun, 터키 (Türkiye), 55139
- 모병
- Ondokuz Mayis Universitesi /ID# 272899
-
Samsun, 터키 (Türkiye), 55200
- 모병
- Samsun Medical Park Hastanesi /ID# 272880
-
-
Antalya
-
Ankara, Antalya, 터키 (Türkiye), 06010
- 모병
- Gulhane Egitim ve Arastirma Hastanesi /ID# 280715
-
-
Sakarya
-
Adapazarı, Sakarya, 터키 (Türkiye), 54290
- 모병
- Sakarya Egitim ve Arastirma Hastanesi /ID# 272878
-
-
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, 폴란드, 20-090
- 모병
- Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie /ID# 273170
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, 폴란드, 15-540
- 모병
- Uniwersytecki Szpital Kliniczny w Bialymstoku /ID# 276848
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, 폴란드, 80-214
- 모병
- Uniwersyteckie Centrum Kliniczne /ID# 272418
-
-
Świętokrzyskie Voivodeship
-
Kielce, Świętokrzyskie Voivodeship, 폴란드, 25-734
- 모병
- Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 274549
-
-
-
-
-
Rio Piedras, 푸에르토 리코, 00935
- 모병
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268827
-
-
-
-
Gironde
-
Bordeaux, Gironde, 프랑스, 33000
- 모병
- Institut Bergonie /ID# 258377
-
-
Loire-Atlantique
-
Saint-Herblain, Loire-Atlantique, 프랑스, 44800
- 모병
- CHU Nantes - Hopital Laennec /ID# 268475
-
Saint-Herblain, Loire-Atlantique, 프랑스, 44805
- 모병
- Institut de Cancerologie de l'Ouest Rene Gauducheau /ID# 268484
-
-
Occitanie
-
Montpellier, Occitanie, 프랑스, 34070
- 모병
- Centre De Cancerologie Du Grand Montpellier /ID# 273724
-
-
Provence-Alpes-Côte d'Azur Region
-
Nice, Provence-Alpes-Côte d'Azur Region, 프랑스, 06189
- 모병
- Centre Antoine-Lacassagne /ID# 268486
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, 프랑스, 94805
- 모병
- Institut Gustave Roussy /ID# 258373
-
-
Île-de-France Region
-
Paris, Île-de-France Region, 프랑스, 75248
- 모병
- Institut Curie /ID# 271395
-
-
-
-
New South Wales
-
Blacktown, New South Wales, 호주, 2148
- 모병
- Blacktown Hospital /ID# 281588
-
-
Queensland
-
Townsville, Queensland, 호주, 4814
- 모병
- Townsville University Hospital /ID# 281498
-
-
South Australia
-
Elizabeth Vale, South Australia, 호주, 5112
- 모병
- Lyell Mcewin Hospital /ID# 281860
-
-
Victoria
-
Frankston, Victoria, 호주, 3199
- 모병
- Peninsula University Hospital /ID# 281824
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study.
- Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
- For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC.
- For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration.
- Must have documented programmed death ligand 1 (PD-L1) status.
- For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization.
- Must have adequate organ function.
Exclusion Criteria:
- Known uncontrolled metastases to the central nervous system.
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part 1: Telisotuzumab Adizutecan + Budigalimab
Participants will receive several doses of telisotuzumab adizutecan in combination with budigalimab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
다른 이름들:
IV Infusion
다른 이름들:
|
|
실험적: Part 2 Arm 1: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose A in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
다른 이름들:
IV Injection IV Infusion |
|
실험적: Part 2 Arm 2: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose B in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
다른 이름들:
IV Injection IV Infusion |
|
실험적: Part 2: Standard of Care
Participants will receive pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed, as part of the 33 month study duration. |
IV Infusion IV Infusion IV Injection IV Infusion IV Infusion |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan
기간: Up to Approximately 84 Days
|
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications. |
Up to Approximately 84 Days
|
|
Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
기간: Up to Approximately 33 Months
|
OR is defined as confirmed complete response (CR) or confirmed partial response (PR) per BICR based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Up to Approximately 33 Months
|
|
Number of Participants with Adverse Events (AE)s
기간: Up to Approximately 33 Months
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 33 Months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1 and Part 2: PFS as Assessed by Investigator
기간: Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression per Investigator based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DOR as Assessed by Investigator
기간: Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR per investigator to the first occurrence of radiographic progression per the investigator on RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DC as Assessed by Investigator
기간: Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 11 weeks following randomization date based on RECIST v1.1, as determined by the Investigator. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: Overall Survival (OS)
기간: Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
Programmed Death Ligand 1 (PD-L1) and c-Met Subgroups: OR
기간: Up to Approximately 33 Months
|
OR is defined as confirmed CR or confirmed PR based on RECIST v1.1. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: PFS
기간: Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: OS
기간: Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DOR
기간: Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DC
기간: Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 12 weeks following randomization date based on RECIST v1.1. |
Up to Approximately 33 Months
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: ABBVIE INC., AbbVie
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- M24-536
- 2024-514465-18 (기타 식별자: EU CT)
- 2024-514465-18-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 공유 기간
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 공유 액세스 기준
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .